EXANTA

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Stroke Prevention in Patients With Atrial FibrillationThromboembolism

Phase 2

Long Term Open Follow-up With H376/95 vs. Warfarin

TerminatedNCT00206063

AstraZenecaStroke Prevention in Patients With Atrial Fibrillation

Start: 1999-08-31End: 2006-04-30Target: 220Updated: 2010-11-15

Phase 3

Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events

TerminatedNCT00206089

AstraZenecaThromboembolism

Start: 2005-09-30End: 2006-08-31Target: 3300Updated: 2010-11-15